Suppressor of cytokine signaling 1 interacts with oncogenic lymphocyte-specific protein tyrosine kinase

Oncology Reports

Volumn 25, Issue 3, 2011, Pages 677-683

  Venkitachalam, Srividya ^a   Chueh, Fu Yu ^a   Leong, King Fu ^a   Pabich, Samantha ^a   Yu, Chao Lan ^a  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

Kinase inhibitor; Lymphocyte specific protein tyrosine kinase; Oncogene; Protein tyrosine kinase; Protein protein interaction; Suppressor of cytokine signaling 1

Indexed keywords

CYTOKINE; CYTOKINE INDUCIBLE SH2 DOMAIN CONTAINING PROTEIN; ONCOPROTEIN; PHOSPHOTYROSINE; PROTEIN; PROTEIN KINASE LCK; PROTEIN TYROSINE KINASE; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 2; SUPPRESSOR OF CYTOKINE SIGNALING 3; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CANCER INHIBITION; CELL TRANSFORMATION; CONTROLLED STUDY; ENZYME ACTIVITY; NEGATIVE FEEDBACK; NONHUMAN; PHOSPHORYLATION AND DEPHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

ANIMALS; CERCOPITHECUS AETHIOPS; COS CELLS; HUMANS; LYMPHOCYTE SPECIFIC PROTEIN TYROSINE KINASE P56(LCK); MUTATION; ONCOGENE PROTEINS; PHOSPHOTRANSFERASES; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN INTERACTION MAPPING; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TRANSFECTION; TYROSINE;

EID: 79551588755     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1144     Document Type: Article

References (28)

1. Sefton BM: The lck tyrosine protein kinase. Oncogene 6: 683-686, 1991.
2. Zamoyska R, Basson A, Filby A, Legname G, Lovatt M and Seddon B: The influence of the src-family kinases, Lck and Fyn, on T cell differentiation, survival and activation. Immunol Rev 191: 107-118, 2003.
3. Salmond RJ, Filby A, Qureshi I, Caserta S and Zamoyska R: T-cell receptor proximal signaling via the Src-family kinases, Lck and Fyn, influences T-cell activation, differentiation, and tolerance. Immunol Rev 228: 9-22, 2009.
4. Shi M, Cooper JC and Yu CL: A constitutively active Lck kinase promotes cell proliferation and resistance to apoptosis through signal transducer and activator of transcription 5b activation. Mol Cancer Res 4: 39-45, 2006.
5. Abraham KM, Levin SD, Marth JD, Forbush KA and Perlmutter RM: Thymic tumorigenesis induced by over-expression of p56lck. Proc Natl Acad Sci USA 88: 3977-3981, 1991.
6. Majolini MB, Boncristiano M and Baldari CT: Dysregulation of the protein tyrosine kinase LCK in lymphoproliferative disorders and in other neoplasias. Leuk Lymphoma 35: 245-254, 1999.
7. Wright DD, Sefton BM and Kamps MP: Oncogenic activation of the Lck protein accompanies translocation of the LCK gene in the human HSB2 T-cell leukemia. Mol Cell Biol 14: 2429-2437, 1994.
8. Amrein KE and Sefton BM: Mutation of a site of tyrosine phosphorylation in the lymphocyte-specific tyrosine protein kinase, p56lck, reveals its oncogenic potential in fibroblasts. Proc Natl Acad Sci USA 85: 4247-4251, 1988.
9. Yu CL, Jove R and Burakoff SJ: Constitutive activation of the Janus kinase-STAT pathway in T lymphoma overexpressing the Lck protein tyrosine kinase. J Immunol 159: 5206-5210, 1997.
10. Yu H and Jove R: The STATs of cancer, new molecular target come of age. Nat Rev Cancer 4: 97-105, 2004.
11. Yoshimura A, Naka T and Kubo M: SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol 7: 454-465, 2007.
12. Alexander WS: Suppressors of cytokine signalling (SOCS) in the immune system. Nat Rev Immunol 2: 410-416, 2002.
13. Liu E, Cote JF and Vuori K: Negative regulation of FAK signaling by SOCS proteins. EMBO J 22: 5036-5046, 2003. (Pubitemid 37222024)
14. Liu L, Gao Y, Qiu H, Miller WT, Poli V and Reich NC: Identification of STAT3 as a specific substrate of breast tumor kinase. Oncogene 25: 4904-4912, 2006.
15. Rottapel R, Ilangumaran S, Neale C, La Rose J, Ho JM, Nguyen MH, Barber D, Dubreuil P and de Sepulveda P: The tumor suppressor activity of SOCS-1. Oncogene 21: 4351-4362, 2002.
16. He B, You L, Uematsu K, Zang K, Xu Z, Lee AY, Costello JF, McCormick F and Jablons DM: SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci USA 100: 14133-14138, 2003.
17. Watanabe D, Ezoe S, Fujimoto M, Kimura A, Saito Y, Nagai H, Tachibana I, Matsumura I, Tanaka T, Kanegane H, Miyawaki T, Emi M, Kanakura Y, Kawase I, Naka T and Kishimoto T: Suppressor of cytokine signalling-1 gene silencing in acute myeloid leukaemia and human haematopoietic cell lines. Br J Haematol 126: 726-735, 2004.
18. Weber A, Hengge UR, Bardenheuer W, Tischoff I, Sommerer F, Markwarth A, Dietz A, Wittekind C and Tannapfel A: SOCS-3 is frequently methylated in head and neck squamous cell carcinoma and its precursor lesions and causes growth inhibition. Oncogene 24: 6699-6708, 2005. (Pubitemid 41486800)
19. Cooper JC, Boustead JN and Yu CL: Characterization of STAT5B phosphorylation correlating with expression of cytokine-inducible SH2-containing protein (CIS). Cell Signal 18: 851-860, 2006.
20. Cooper JC, Shi M, Chueh FY, Venkitachalam S and Yu CL: Enforced SOCS1 and SOCS3 expression attenuates Lck-mediated cellular transformation. Int J Oncol 36: 1201-1208, 2010.
21. Yamaguchi H and Hendrickson WA: Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation. Nature 384: 484-489, 1996.
22. Yasukawa H, Misawa H, Sakamoto H, Masuhara M, Sasaki A, Wakioka T, Ohtsuka S, Imaizumi T, Matsuda T, Ihle JN and Yoshimura A: The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J 18: 1309-1320, 1999.
23. Suzuki A, Hanada T, Mitsuyama K, Yoshida T, Kamizono S, Hoshino T, Kubo M, Yamashita A, Okabe M, Takeda K, Akira S, Matsumoto S, Toyonaga A, Sata M and Yoshimura A: CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation. J Exp Med 193: 471-481, 2001.
24. Sasaki A, Yasukawa H, Shouda T, Kitamura T, Dikic I and Yoshimura A: CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2. J Biol Chem 275: 29338-29347, 2000. (Pubitemid 32043805)
25. Sasaki A, Yasukawa H, Suzuki A, Kamizono S, Syoda T, Kinjyo I, Sasaki M, Johnston JA and Yoshimura A: Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain. Genes Cells 4: 339-351, 1999.
26. Giannini A and Bijlmakers MJ: Regulation of the Src family kinase Lck by Hsp90 and ubiquitination. Mol Cell Biol 24: 5667-5676, 2004.
27. Masuhara M, Sakamoto H, Matsumoto A, Suzuki R, Yasukawa H, Mitsui K, Wakioka T, Tanimura S, Sasaki A, Misawa H, Yokouchi M, Ohtsubo M and Yoshimura A: Cloning and characterization of novel CIS family genes. Biochem Biophys Res Commun 239: 439-446, 1997.
28. Iwamoto T, Senga T, Naito Y, Matsuda S, Miyake Y, Yoshimura A and Hamaguchi M: The JAK-inhibitor, JAB/SOCS-1 selectively inhibits cytokine-induced, but not v-Src induced JAK-STAT activation. Oncogene 19: 4795-4801, 2000.